{"url_path":"/sec/xoma/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-302648-index.html","accession_number":"0001193125-26-302648","cik":"0000791908","ticker":"XOMA","issuer_name":"XOMA Royalty Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/791908/0001193125-26-302648-index.html","primary_entity_key":"0000791908","primary_entity_name":"XOMA Royalty Corp"},"word_count":287,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n  \nDescription\n\n 2.1*\n  \n[Agreement and Plan of Merger, dated as of April 27, 2026, by and among XOMA Royalty Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2026).](http://www.sec.gov/Archives/edgar/data/791908/000119312526179085/d139894dex21.htm)\n\n 2.2\n  \n[Amendment No. 1 to the Agreement and Plan of Merger, dated as of May 16, 2026, by and among XOMA Royalty Corporation, XOMA Royalty Holdings Corporation, Ligand Pharmaceuticals Incorporated and Flex Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2026).](http://www.sec.gov/Archives/edgar/data/791908/000119312526228031/d130820dex21.htm)\n\n10.1*\n  \n[Form of Support Agreement, dated as of April 27, 2026, entered into by Ligand Pharmaceuticals Incorporated, Flex Merger Sub, Inc. and the Supporting Stockholders (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 27, 2026).](http://www.sec.gov/Archives/edgar/data/791908/000119312526179085/d139894dex101.htm)\n\n99.1\n  \n[Press Release of XOMA Royalty Corporation, dated July 14, 2026.](d165297dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nCertain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nXOMA ROYALTY CORPORATION\n\nDate: July 14, 2026\n \n\n \nBy:\n \n\n/s/ Jeffrey Trigilio\n\n \n\n \n\n \nJeffrey Trigilio\n\n \n\n \n\n \nChief Financial Officer"}